Table 4 The model’s results considering the effect of new and generic drugs alone
2015 | 2016 | 2017 | 2018 | 2019 | ||
|---|---|---|---|---|---|---|
Number of patients | 94,727 | 99,205 | 103,893 | 108,804 | 113,946 | |
New antiretroviral drugs scenario | Total ART cost (€) | 780,148,483 | 815,891,938 | 845,063,294 | 885,581,470 | 929,655,763 |
Per capita ART cost (€) | 8,236 | 8,224 | 8,134 | 8,139 | 8,159 | |
Δ in total cost (€) compared to base case | +15,186,448 | +26,880,786 | +31,666,260 | +47,465,974 | +66,496,550 | |
% Δ in total cost | +2.0 % | +3.4 % | +3.9 % | +5.7 % | +7.7 % | |
Generic drugs scenario | Total ART cost (€) | 759,981,491 | 770,436,043 | 790,580,416 | 761,583,789 | 675,775,852 |
Per capita ART cost (€) | 8,023 | 7,766 | 7,610 | 7,000 | 5,931 | |
Δ in total cost (€) | −4,980,545 | −18,575,109 | −22,816,617 | −76,531,708 | −187,383,361 | |
% Δ in total cost | −0.7 % | −2.4 % | −2.8 % | −9.1 % | −21.7 % | |